The International Gynecologic Oncology Consensus Conference: Marrying Evidence to Practice
Accreditation: 9.75 ABIM MOC II | 9.75 AMA PRA Category 1 Credit™ | 9.75 ACPE Pharmacy
Venue: Hyatt Regency Boston, One Avenue de Lafayette, Boston, MA, 02111, United States
Official conference page for The International Gynecologic Oncology Consensus Conference: Marrying Evidence to Practice . https://binaytara.org/projects/conferences/the-international-gynecologic-oncology-consensus-conference-marrying-evidence-to-practice-1
About The International Gynecologic Oncology Consensus Conference: Marrying Evidence to Practice


Faculty and committee
Our Speakers
Planning Committee
Faculty
Conference program and agenda
Agenda
Day 1: Friday, November 6th, 2026
All timings are in Eastern Time (EDT, GMT-04:00) time.
Session Chair: Anuja Jhingran, MD
01:20 PM - 01:30 PM
Molecular staging of endometrial cancer: approach to p53 abnormal tumors – Carol Aghajanian, MD
01:30 PM - 01:40 PM
A critical review of the role of radiation in early-stage endometrial cancer – Ann Hoge Klopp, MD
01:40 PM - 02:10 PM
Discussion
Moderators:
Anuja Jhingran, MD
Panelists:
Carol Aghajanian, MD; Ann Hoge Klopp, MD; Daniela Matei, MD; Floortje Backes, MD, MBA
02:10 PM - 02:25 PM
Vote (audience participation, panel vote)
Session Chair: Stephanie Lherueux, MD
02:40 PM - 02:50 PM
Adjuvant PARP inhibitors: Update on long-term benefit – Robert Coleman, MD
02:50 PM - 03:00 PM
Is there a role for PARPi after progression on a prior PARPi? – Joyce Liu, MD
03:00 PM - 03:30 PM
Discussion
Moderators:
Stephanie Lherueux, MD
Panelists:
Robert Coleman, MD; Joyce Liu, MD; Jason Wright, MD; Jonathan Andrew Ledermann, MD
03:30 PM - 03:45 PM
Vote (audience participation, panel vote)
Session Chair: Linda Duska, MD
04:00 PM - 04:10 PM
The current state of FOLR1 directed treatments: mirvetuximab and beyond – Kathleen Kathleen, MD
04:10 PM - 04:20 PM
B96 Trial – Nicoletta Colombo, MD
04:20 PM - 04:30 PM
Rosella – Alexander B Olawaiye, MD
04:30 PM - 05:00 PM
Discussion
Moderators:
Linda Duska, MD
Panelists:
Kathleen Kathleen, MD; Nicoletta Colombo, MD; Alexander B Olawaiye, MD; Debra Richardson, MD; Premal Thaker, MD
05:00 PM - 05:15 PM
Vote (audience participation, panel vote)
Day 2: Saturday, November 7th, 2026
Session Chair: Dmitriy Dmitriy, MD
08:05 AM - 08:15 AM
The role of ADCs in endometrial cancer – Noelle Cloven, MD
08:15 AM - 08:25 AM
Targeting HER2: is earlier better? – Amanda Nickles Fader, MD
08:25 AM - 08:55 AM
Discussion
Moderators:
Dmitriy Dmitriy, MD
Panelists:
Noelle Cloven, MD; Amanda Nickles Fader, MD; Stephanie Gaillard, MD
08:55 AM - 09:10 AM
Vote (audience participation, panel vote)
Session Chair: Katina Robison, MD
09:20 AM - 09:30 AM
The role of checkpoint inhibitors in dMMR endometrial cancer – Ramez Eskander, MD
09:30 AM - 09:40 AM
Options and endpoints with adjuvant RT for endometrial cancer – Alexandra Taylor, MD
09:40 AM - 10:00 AM
Discussion
Moderators:
Katina Robison, MD
Panelists:
Don Steven Dizon, MD; Ramez Eskander, MD; Alexandra Taylor, MD
10:00 AM - 10:15 AM
POLE-endometrial cancer: Does stage matter? – Jessica N. Mcalpine, MD
10:15 AM - 10:35 AM
Discussion
Moderators:
Katina Robison, MD
Panelists:
David Mutch, MD; Jessica N. Mcalpine, MD; David Huntsman
10:35 AM - 10:45 AM
A critical evaluation of checkpoint inhibitors in cervical cancer: PD-L1 and beyond – Trey Leath, MD
10:45 AM - 11:05 AM
Discussion
Moderators:
Katina Robison, MD
Panelists:
Trey Leath, MD; Denis Querleu ; Paul A DiSilvestro, MD
11:05 AM - 11:20 AM
Vote (audience participation, panel vote)
